Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience

详细信息	查看全文 | 推荐本文 |

• 作者：Michael J. Zelefsky¹ ; ^{zelefskm@mskcc.org} ; Joanne F. Chou² ; Xin Pei¹ ; Yoshiya Yamada¹ ; Marisa Kollmeier¹ ; Brett Cox¹ ; Zhigang Zhang² ; Michael Schechter¹ ; Gil’ ; ad N. Cohen³ ; Marco Zaider³
• 关键词：Brachytherapy ; Prostate cancer ; Prostate-specific antigen ; Nomogram ; Iodine-125 ; D90
• 刊名：Brachytherapy
• 出版年：2012
• 期刊代码：278_15384721
• 类别：med
• 出版时间：July-August, 2012
• 卷：11
• 期：4
• 页码：245-249
• 文件大小：249 K

摘要

Purpose

To identify predictors of biochemical tumor control and present an updated prognostic nomogram for patients with clinically localized prostate cancer treated with brachytherapy.

Methods and Materials

One thousand four hundred sixty-six patients with clinically localized prostate cancer were treated with brachytherapy alone or along with supplemental conformal radiotherapy. Nine hundred one patients (61%) were treated with Iodine-125 (¹²⁵I) monotherapy to a prescribed dose of 144 Gy, and 41 (4.5%) were treated with Palladium-103 (¹⁰³Pd) monotherapy to a prescribed dose of 125 Gy. In patients with higher risk features (n = 715), a combined modality approach was used, which comprised ¹²⁵I or ¹⁰³Pd seed implantation or Iridium-192 high-dose rate brachytherapy followed 1-2 months later by supplemental intensity-modulated image-guided radiotherapy to the prostate.

Results

The 5-year prostate-specific antigen relapse-free survival (PSA-RFS) outcomes for favorable-, intermediate-, and high-risk patients were 98%, 95%, and 80%, respectively (p < 0.001). Multivariate Cox regression analysis identified Gleason score (p < 0.001) and pretreatment PSA (p = 0.04) as predictors for PSA tumor control. In this cohort of patients, the use of neoadjuvant and concurrent androgen deprivation therapy did not influence biochemical tumor control outcomes. In the subset of patients treated with ¹²⁵I monotherapy, D₉₀ > 140 Gy compared with lower doses was associated with improved PSA-RFS. A nomogram predicting PSA-RFS was developed based on these predictors and had a concordance index of 0.70.

Conclusions

Results with brachytherapy for all treatment groups were excellent. D₉₀ higher than 140 Gy was associated with improved biochemical tumor control compared with lower doses. Androgen deprivation therapy use did not impact on tumor control outcomes in these patients.